The European Medicines Company’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has urged an distinctive instances advertising authorization for Imreplys. The drug — active ingredient sargramostim and manufactured by Associate Therapeutics Ltd — is supposed to handle folks with hematopoietic acute radiation syndrome (H-ARS) following acute publicity to myelosuppressive doses of radiation. …
Read Extra
